|
1
|
Icardi L, De Bosscher K and Tavernier J:
The HAT/HDAC interplay: multilevel control of STAT signaling.
Cytokine Growth Factor Rev. 23:283–291. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lu Z, Luo RZ, Peng H, et al: E2F-HDAC
complexes negatively regulate the tumor suppressor gene ARHI in
breast cancer. Oncogene. 25:230–239. 2006.PubMed/NCBI
|
|
3
|
Khan O and La Thangue NB: HDAC inhibitors
in cancer biology: emerging mechanisms and clinical applications.
Immunol Cell Biol. 90:85–94. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cebrian A, Pharaoah PD, Ahmed S, et al:
Genetic variants in epigenetic genes and breast cancer risk.
Carcinogenesis. 27:1661–1669. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang L, Zou X, Berger AD, et al: Increased
expression of histone deacetylaces (HDACs) and inhibition of
prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J
Transl Res. 1:62–71. 2009.PubMed/NCBI
|
|
6
|
Robey RW, Chakraborty AR, Basseville A, et
al: Histone deacetylase inhibitors: emerging mechanisms of
resistance. Mol Pharm. 8:2021–2031. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pettazzoni P, Pizzimenti S, Toaldo C, et
al: Induction of cell cycle arrest and DNA damage by the HDAC
inhibitor panobinostat (LBH589) and the lipid peroxidation end
product 4-hydroxynonenal in prostate cancer cells. Free Radic Biol
Med. 50:313–322. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Frumm SM, Fan ZP, Ross KN, et al:
Selective HDAC1/HDAC2 inhibitors induce neuroblastoma
differentiation. Chem Biol. 20:713–725. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rikiishi H: Autophagic and apoptotic
effects of HDAC inhibitors on cancer cells. J Biomed Biotechnol.
2011:8302602011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lauricella M, Ciraolo A, Carlisi D, et al:
SAHA/TRAIL combination induces detachment and anoikis of MDA-MB231
and MCF-7 breast cancer cells. Biochimie. 94:287–299. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Carlisi D, Lauricella M, D’Anneo A, et al:
The histone deacetylase inhibitor suberoylanilide hydroxamic acid
sensitises human hepatocellular carcinoma cells to TRAIL-induced
apoptosis by TRAIL-DISC activation. Eur J Cancer. 45:2425–2438.
2009. View Article : Google Scholar
|
|
12
|
Al-Yacoub N, Fecker LF, Mobs M, et al:
Apoptosis induction by SAHA in cutaneous T-cell lymphoma cells is
related to downregulation of c-FLIP and enhanced TRAIL signaling. J
Invest Dermatol. 132:2263–2274. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gong K, Xie J, Yi H and Li W: CS055
(Chidamide/HBI-8000), a novel histone deacetylase inhibitor,
induces G1 arrest, ROS-dependent apoptosis and differentiation in
human leukaemia cells. Biochem J. 443:735–746. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang BH, Laban M, Leung CH, et al:
Inhibition of histone deacetylase 2 increases apoptosis and
p21Cip1/WAF1 expression, independent of histone
deacetylase 1. Cell Death Differ. 12:395–404. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Anton M, Horky M, Kuchtickova S, et al:
Immunohistochemical detection of acetylation and phosphorylation of
histone H3 in cervical smears. Ceska Gynekol. 69:3–6.
2004.PubMed/NCBI
|
|
16
|
Shan Z, Feng-Nian R, Jie G and Ting Z:
Effects of valproic acid on proliferation, apoptosis, angiogenesis
and metastasis of ovarian cancer in vitro and in vivo. Asian Pac J
Cancer Prev. 13:3977–3982. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Machado MC, Bellodi-Privato M, Kubrusly
MS, et al: Valproic acid inhibits human hepatocellular cancer cells
growth in vitro and in vivo. J Exp Ther Oncol. 9:85–92.
2011.PubMed/NCBI
|
|
18
|
Han YH, Moon HJ, You BR, et al: Effects of
carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone on the growth
inhibition in human pulmonary adenocarcinoma Calu-6 cells.
Toxicology. 265:101–107. 2009. View Article : Google Scholar
|
|
19
|
You BR and Park WH: Zebularine inhibits
the growth of HeLa cervical cancer cells via cell cycle arrest and
caspase-dependent apoptosis. Mol Biol Rep. 39:9723–9731. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Han YH, Moon HJ, You BR and Park WH: The
effect of MG132, a proteasome inhibitor on HeLa cells in relation
to cell growth, reactive oxygen species and GSH. Oncol Rep.
22:215–221. 2009.PubMed/NCBI
|
|
21
|
You BR and Park WH: Proteasome inhibition
by MG132 induces growth inhibition and death of human pulmonary
fibroblast cells in a caspase-independent manner. Oncol Rep.
25:1705–1712. 2011.PubMed/NCBI
|
|
22
|
Han YH, Kim SH, Kim SZ and Park WH:
Carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone (FCCP) as an
O2(*-) generator induces apoptosis via the depletion of
intracellular GSH contents in Calu-6 cells. Lung Cancer.
63:201–209. 2009.
|
|
23
|
Han YH and Park WH: Propyl gallate
inhibits the growth of HeLa cells via regulating intracellular GSH
level. Food Chem Toxicol. 47:2531–2538. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Griffiths EJ: Mitochondria - potential
role in cell life and death. Cardiovasc Res. 46:24–27. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
You BR and Park WH: Suberoyl bishydroxamic
acid-induced apoptosis in HeLa cells via ROS-independent,
GSH-dependent manner. Mol Biol Rep. 40:3807–3816. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gurvich N, Tsygankova OM, Meinkoth JL and
Klein PS: Histone deacetylase is a target of valproic acid-mediated
cellular differentiation. Cancer Res. 64:1079–1086. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhao X, Yang W, Shi C, et al: The G1 phase
arrest and apoptosis by intrinsic pathway induced by valproic acid
inhibit proliferation of BGC-823 gastric carcinoma cells. Tumour
Biol. 32:335–346. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Das CM, Aguilera D, Vasquez H, et al:
Valproic acid induces p21 and topoisomerase-II (α/β) expression and
synergistically enhances etoposide cytotoxicity in human
glioblastoma cell lines. J Neurooncol. 85:159–170. 2007.PubMed/NCBI
|
|
29
|
Yang J, Liu X, Bhalla K, et al: Prevention
of apoptosis by Bcl-2: release of cytochrome c from mitochondria
blocked. Science. 275:1129–1132. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Eot-Houllier G, Fulcrand G,
Magnaghi-Jaulin L and Jaulin C: Histone deacetylase inhibitors and
genomic instability. Cancer Lett. 274:169–176. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ungerstedt JS, Sowa Y, Xu WS, et al: Role
of thioredoxin in the response of normal and transformed cells to
histone deacetylase inhibitors. Proc Natl Acad Sci USA.
102:673–678. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Han YH, Kim SZ, Kim SH and Park WH:
Enhancement of arsenic trioxide-induced apoptosis in HeLa cells by
diethyldithiocarbamate or buthionine sulfoximine. Int J Oncol.
33:205–213. 2008.PubMed/NCBI
|
|
33
|
Estrela JM, Ortega A and Obrador E:
Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci.
43:143–181. 2006. View Article : Google Scholar
|
|
34
|
Han YH, Kim SZ, Kim SH and Park WH:
Suppression of arsenic trioxide-induced apoptosis in HeLa cells by
N-acetylcysteine. Mol Cells. 26:18–25. 2008.PubMed/NCBI
|
